Bank Of Montreal Chemo Centryx, Inc. Transaction History

Bank Of Montreal

$214 Billion
Q3 2024

Shares

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 10, 2022	SELL	$22.17 - $51.8 $1,086 - $2,538	-49 Reduced 0.6%	8,155 $422,000
Q2 2022 Aug 11, 2022	SELL	$15.36 - $27.51 $8,816 - $15,790	-574 Reduced 6.54%	8,204 $213,000
Q1 2022 May 12, 2022	BUY	$22.22 - $39.12 $2,288 - $4,029	103 Added 1.19%	8,778 $219,000
Q4 2021 Feb 11, 2022	SELL	$18.38 - $40.5 $1.61 Million - $3.54 Million	-87,475 Reduced 90.98%	8,675 $321,000
Q3 2021 Nov 12, 2021	BUY	$13.18 - $19.83 $12,402 - $18,660	941 Added 0.99%	96,150 $1.88 Million
Q2 2021 Aug 12, 2021	BUY	$9.59 - $50.88 $913,054 - $4.84 Million	95,209 New	95,209 $1.34 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.